Low-level HBV viremia independently predicts poor outcomes in patients with intermediate-to-advanced HBV-related hepatocellular carcinoma receiving systemic therapy: a multicenter retrospective study.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
1814 patients treated at three centers between 2020 and 2024 were retrospectively enrolled.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Baseline HBV DNA load was not associated with survival. [CONCLUSION] LLV is a robust, independent indicator of poor prognosis in systemic-treated intermediate-to-advanced HBV-HCC and should be preferred to baseline HBV DNA load for risk stratification and to guide intensified antitumor therapy.
[BACKGROUND] Low-level hepatitis B viremia is recognized as a potential driver of hepatocarcinogenesis; however, its prognostic impact on patients with advanced hepatocellular carcinoma (HCC) receivin
- 95% CI 1.53-2.541
- 연구 설계 cohort study
APA
Lei J, Ma H, et al. (2026). Low-level HBV viremia independently predicts poor outcomes in patients with intermediate-to-advanced HBV-related hepatocellular carcinoma receiving systemic therapy: a multicenter retrospective study.. Therapeutic advances in medical oncology, 18, 17588359261435330. https://doi.org/10.1177/17588359261435330
MLA
Lei J, et al.. "Low-level HBV viremia independently predicts poor outcomes in patients with intermediate-to-advanced HBV-related hepatocellular carcinoma receiving systemic therapy: a multicenter retrospective study.." Therapeutic advances in medical oncology, vol. 18, 2026, pp. 17588359261435330.
PMID
41970939 ↗
Abstract 한글 요약
[BACKGROUND] Low-level hepatitis B viremia is recognized as a potential driver of hepatocarcinogenesis; however, its prognostic impact on patients with advanced hepatocellular carcinoma (HCC) receiving systemic therapy remains poorly defined.
[OBJECTIVE] To determine the independent prognostic impact of low-level viremia (LLV; HBV DNA 20-2000 IU/mL) compared with maintained virologic response (MVR; HBV DNA < 20 IU/mL) in patients with intermediate-to-advanced HBV-related HCC undergoing systemic therapy, and to evaluate whether on-treatment viral status serves as a superior predictor to baseline HBV DNA levels.
[DESIGN] This was a multicenter retrospective cohort study.
[METHODS] A total of 1814 patients treated at three centers between 2020 and 2024 were retrospectively enrolled. After ⩾4 months of follow-up, patients were classified into LLV ( = 860) or maintained virologic response (MVR; HBV DNA < 20 IU/mL, = 954) groups. Overall survival (OS) and progression-free survival (PFS) were the primary endpoints. Logistic regression identified risk factors for LLV; Cox proportional hazards models assessed independent prognostic factors. Subgroup analyses were performed by treatment regimen and baseline HBV DNA load.
[RESULTS] Multifactorial analysis identified HBeAg positivity (OR 1.971, 95% CI 1.53-2.541, < 0.001), AST > 40 U/L (OR 1.437, 95% CI 1.126-1.832, = 0.004), extrahepatic metastasis (OR 1.640, 95% CI 1.187-2.266, = 0.003), and detectable baseline HBV DNA (OR 2.482, 95% CI 2.002-3.077, < 0.001) as independent risk factors for LLV. Compared with the MVR group, patients in the LLV group had significantly reduced PFS (8.3 vs 14.3 months, < 0.001) and OS (25.5 vs 37.8 months, < 0.001). Multivariate analysis identified LLV as an independent predictor of worse OS (HR 1.506, 95% CI 1.299-1.746). Baseline HBV DNA load was not associated with survival.
[CONCLUSION] LLV is a robust, independent indicator of poor prognosis in systemic-treated intermediate-to-advanced HBV-HCC and should be preferred to baseline HBV DNA load for risk stratification and to guide intensified antitumor therapy.
[OBJECTIVE] To determine the independent prognostic impact of low-level viremia (LLV; HBV DNA 20-2000 IU/mL) compared with maintained virologic response (MVR; HBV DNA < 20 IU/mL) in patients with intermediate-to-advanced HBV-related HCC undergoing systemic therapy, and to evaluate whether on-treatment viral status serves as a superior predictor to baseline HBV DNA levels.
[DESIGN] This was a multicenter retrospective cohort study.
[METHODS] A total of 1814 patients treated at three centers between 2020 and 2024 were retrospectively enrolled. After ⩾4 months of follow-up, patients were classified into LLV ( = 860) or maintained virologic response (MVR; HBV DNA < 20 IU/mL, = 954) groups. Overall survival (OS) and progression-free survival (PFS) were the primary endpoints. Logistic regression identified risk factors for LLV; Cox proportional hazards models assessed independent prognostic factors. Subgroup analyses were performed by treatment regimen and baseline HBV DNA load.
[RESULTS] Multifactorial analysis identified HBeAg positivity (OR 1.971, 95% CI 1.53-2.541, < 0.001), AST > 40 U/L (OR 1.437, 95% CI 1.126-1.832, = 0.004), extrahepatic metastasis (OR 1.640, 95% CI 1.187-2.266, = 0.003), and detectable baseline HBV DNA (OR 2.482, 95% CI 2.002-3.077, < 0.001) as independent risk factors for LLV. Compared with the MVR group, patients in the LLV group had significantly reduced PFS (8.3 vs 14.3 months, < 0.001) and OS (25.5 vs 37.8 months, < 0.001). Multivariate analysis identified LLV as an independent predictor of worse OS (HR 1.506, 95% CI 1.299-1.746). Baseline HBV DNA load was not associated with survival.
[CONCLUSION] LLV is a robust, independent indicator of poor prognosis in systemic-treated intermediate-to-advanced HBV-HCC and should be preferred to baseline HBV DNA load for risk stratification and to guide intensified antitumor therapy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Liquid-gas phase-change nanoplatforms for ultrasound-mediated cancer theranostics.
- Cancer Stem Cells Shift Metabolite Acetyl-Coenzyme A to Abrogate the Differentiation of CD103 T Cells.
- Indicators to identify cancer screening providers with suboptimal case detection: A scoping review.
- Association between cholesterol and liver injury risk in solid cancer patients treated with PD-1 inhibitors: evidence from two cohort studies.
- Pancreatic-targeted lipid nanoparticles based on organ capsule filtration.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.
- Heat Shock Protein 47 as a Novel Predictive and Diagnostic Biomarker for Thrombosis in Hepatocellular Carcinoma.
- Crosstalk Between -Regulatory Elements and Metabolism Reprogramming in Hepatocellular Carcinoma.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- Risks, Benefits, and Molecular Targets of Fenugreek Administration in the Treatment of Hepatocellular Carcinoma.
- Machine learning integrating MRI and clinical features predicts early recurrence of hepatocellular carcinoma after resection.